STAPLED PEPTIDE THERAPEUTIC FOR NON-DRUGGABLE TARGETS

THERAPEUTICS
Platform technology that manipulates α-helical peptides to improve half-life, cell permeability, lower immunogenicity, decrease dosing requirements and improve the therapeutic window.

TECHNOLOGY TYPE
Platform Method
Biologics
Peptides

STAGE OF DEVELOPMENT
- Proof of concept established in cell-based assays.
- Multiple peptides for cancer and diabetes therapeutics in development.

IP PROTECTION
Nationalized PCT Pending in the United States and Europe
Thiol-ene based peptide stapling and uses thereof
WO2016209978A2
Additional Patent Pending in the United States
Thiol-yne based peptide stapling and uses thereof
WO2018017485A1

LEARN MORE
Reference Number: U-5872

Aaron Duffy
Technology Manager
aaron.duffy@tvc.utah.edu
801-585-1377

TECHNOLOGY SUMMARY
Existing therapeutic platforms and drug arsenals utilize small molecules and large antibody proteins, addressing only 20 percent of the druggable market. The chemical space required for inhibition of protein-protein interactions is considered “undruggable” and remains underexplored. Undesirable properties of peptides such as instability, lack of cell/tissue penetration, and immunogenicity of synthetics compound the problem and make it unsuitable for use in humans.

The new method is a proprietary facile and efficient synthetic platform method to generate high yield stapled peptides involving macrocyclization and a two-component thiol-ene based reaction.

FEATURES AND BENEFITS
- Increases shelf and serum half-life.
- Lowers risk for immunogenicity with “stapling” of native amino acids.
- Amenable to large scale synthesis with high yield of stapling.
- Improves pharmacologic performance through linking of functional groups and peptides.
- Provides better selectivity through drug conjugations.

RECENT PUBLICATIONS

INVENTOR PROFILE
Danny Chou, Ph.D., Assistant Professor - Biochemistry
Yuanxiang Wang, Ph.D., Post-Doctorate Fellow

DATE UPDATED: 7/15/2019